In addition, the use of both single-agent CAR-T as well as combined agent anti-tumor CAR-T specific for antigen erythropoietin-producing HCC A2 (EphA2) on FAP+ CAF were reported [366,367]. The gene discussed is FAP; the disease is neoplasm.